RESCUEFLOW APPROVED FOR INITIAL RESUSCITATION AFTER TRAUMA.

RescueFlow, recently approved hypertonic colloid, was specifically designed for safe and effective small volume resuscitation in trauma and haemorrhagic shock. Both active components, hypertonic (7,5%) saline and 6% dextran 70, play a decisive role in rapidly expanding and sustaining plasma volume. The dextran component binds the recruited water within the intravascular space, thus sustaining the volume expansion achieved and stabilising haemodynamics.

In the trauma patient the rapid and efficient volume replacement achieved by RescueFlow(R) supports central haemodynamics and improves microcirculatory flow. In particular, extensive experimental documentation demonstrates that.

RescueFlow(R) has shown to improve survival in a recent multicenter clinical trial. ( Ref 1 ). in patients who were hypotensive and sustained traumatic brain injury . Significant survival benefits were observed for more severely traumatised patient groups, such as those requiring surgery for penetrating injuries, although the overall improvement in survival was not statistically significant.(Ref 2) Ref 1 ( Ref. Journal of Trauma, Vol.42 No 5 1997 ) Ref 2 ( Ref Acta Anaesthesiologica Scand.Suppl. 1997:110 77-79)

Visit the RescueFlow(R) web-site at www.rescueflow.com for further information.

Events during 2000

BioPhausia has signed an exclusive agreement with Curatis GmbH regarding the distribution rights for the hospital product. Emergency Care units and hospital specialists are the target group. It is the same target group as for the core product, RescueFlow(R). This is in line with the new market-oriented direction of the company.

The agreement includes Germany, Sweden and Norway with the option for more markets at global level. BioPhausia is evaluating more potential products to acquire or licensing.

BioPhausia signed a distribution agreement with Genmedix Limited for Israel.

Biophausia has signed a distribution agreement with Genmedix Ltd, a company in the Merck group, for Israel. Israel is a strategic market for RescueFlow(R). The regulatory process of RescueFlow(R) is ongoing. The agreement with Israel is following the business plan of the company for the global introduction of RescueFlow(R).

BioPhausia has signed an distribution agreement for Inno Pharm GmbH, which will be one of the sub distributors in Germany. Inno Pharm will be focusing on the military market segment . BioPhausia will improve the possibilities for market penetration on this major pharmaceutical market .

Military research institutes has since the start been the leading driving forces when it comes to the research on RescueFlow(R). An evaluation order has been received from the military Germany.

In connection with the introduction of RescueFlow(R), BioPhausia has opened a sales representation office in Germany .The German pharmaceutical market is one of the largest in Europe, and a sales office combined with a number of sub distributors provides BioPhausia with a more efficient way to influence the market, as well as better service for customers.

BioPhausia Management has during the period focused its operations on negotiations with future distributors in the countries where RescueFlow(R) is approved for marketing. These efforts have resulted in a distribution agreement with Laboratoires Belamont, France, regarding sales of RescueFlow(R). Laboratoires Belamont is part of the Cider Sant Group, which is one of the leading pharmaceutical organisations in France and the French speaking countries in Africa. The agreement covers France, 24 countries in Africa, and a further nine territories under French rule. Sales are expected to commence after the local administrative and business processes have been completed.

BioPhausia has signed a distribution agreement with the pharmaceutical company BioQuest GmbH. The agreement makes BioQuest one of Biophausia@s sub distributors in Germany. The established BioQuest customers will become available to BioPhausia, and thus the company will be able to provide its customers with better service. Negotiations are under way with further distributors, according to plans. Sales are expected to commence during the third quarter of the year.

In Germany a study on RescueFlow(R) used in surgery has been concluded. RescueFlow(R) has been compared with standard of care on abdominal aortic aneurysm surgery. The initial results from the study indicate that RescueFlow(R), when administered during surgery, maintains the circulation of the patient with less volume than with standard of care. These results, in combination with other available documentation, indicate that RescueFlow(R) may provide more efficient volume substitution during surgery. This suggests that the indication area for RescueFlow(R) could be extended. The project is running on time.

BioPhausia AB is an innovative Swedish pharmaceutical company listed on the Swedish Stock Exchange.

For more information, visit http://www.biophausia.se and http://www.rescueflow.com or call [phone].